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Influence of the Proton Pump Inhibitor 
Esomeprazole on the Bioavailability of 
Regorafenib: A Randomized Crossover 
Pharmacokinetic Study
Femke M. de Man1 , Koen G.A.M. Hussaarts1, Mirjam de With1, Esther Oomen-de Hoop1,  
Peter de Bruijn1, Henk K. van Halteren2, Nicole C.H.P. van der Burg-de Graauw3, Ferry A.L.M. Eskens1, 
Teun van Gelder4, Roelof W.F. van Leeuwen1,4 and Ron H.J. Mathijssen1
Regorafenib exposure could potentially be influenced by an interaction with acid- reducing drugs. In this crossover 
trial, patients were randomized into two sequence groups consisting of three phases: regorafenib intake alone, 
regorafenib with concomitant esomeprazole, and regorafenib with esomeprazole 3 hours prior. The primary end point 
was the relative difference (RD) in geometric means for regorafenib 0–24- hour area under the concentration- time 
curve (AUC0–24h) and was analyzed by a linear mixed model in 14 patients. AUC0–24h for regorafenib alone was 
55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with 
esomeprazole 3 hours prior AUC0–24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively. 
No significant differences were identified when regorafenib alone was compared with regorafenib with concomitant 
esomeprazole (RD: −3.9%; 95% confidence interval (CI): −20.5 to 16.1%; P = 1.0) or regorafenib with esomeprazole 
3 hours prior (RD: −4.1%; 95% CI: −22.8 to 19.2%; P = 1.0). These findings indicate that regorafenib and 
esomeprazole can be safely combined in clinical practice.
Regorafenib is an oral multikinase inhibitor that targets angio-
genic, stromal, and oncogenic receptor tyrosine kinases (e.g., 
vascular endothelial growth factor receptor, KIT, B- type Raf, 
platelet- derived growth factor receptor, and fibroblast growth 
factor receptor).1 It is currently registered for metastatic colorec-
tal cancer (mCRC), gastrointestinal stromal tumor (GIST), and 
hepatocellular carcinoma (HCC).2–4 Regorafenib is the first 
and currently only tyrosine kinase inhibitor (TKI) registered 
for mCRC, although the median overall survival increase for an 
unselected group in the third or fourth line of treatment is only 
1.4 months compared with placebo.2 For HCC and GIST, rego-
rafenib provides a stronger survival benefit as second and third 
line TKI- based therapy.3,4 For several TKIs, systemic exposure 
has been demonstrated to influence toxicity and efficacy.5,6
After oral administration, regorafenib is rapidly absorbed, with 
a time of maximum concentration (Tmax) reached at 3–4 hours.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 For several kinase inhibitors, reduced absorption and de-
creased exposure were demonstrated with concurrent use of 
acid reducing drugs like PPIs. However, there is no knowledge 
about this potential DDI with regorafenib.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This is the first randomized pharmacokinetic crossover trial 
investigating the influence of esomeprazole on regorafenib 
pharmacokinetics, including a potential time- dependency of 
this interaction.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 No significant pharmacokinetic interaction was observed 
between regorafenib and esomeprazole (used concomitantly or 
3 hours prior to regorafenib intake), and, therefore, these two 
drugs can be combined safely in clinical practice.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 A clinically relevant DDI between regorafenib and esome-
prazole was ruled out in a unique study design, which could 
serve as a template for future studies evaluating the influence of 
PPIs on exposure of oral (anticancer) drugs.
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Most TKIs exhibit pH- dependent solubility.8 For regorafenib, 
a low basic predicted pKa of around 2 suggests influence of the 
gastrointestinal pH on the absorption; however, this is not clearly 
demonstrated.9,10 Although the physiochemical properties of re-
gorafenib may not predict significant pH- dependent solubility, 
regorafenib absorption is multifactorial and may be affected by the 
concomitant use of acid- reducing drugs.11 For many TKIs, a phar-
macokinetic interaction with an acid- suppressive agent has already 
been demonstrated; for example, erlotinib combined with omepra-
zole resulted in 46% decrease in systemic exposure.8 However, for 
some TKIs this interaction could be ruled out. To our knowledge, 
for regorafenib there is no study available yet on a possible drug–
drug interaction (DDI) with acid- reducing drugs.
When the exposure is decreased, the efficacy of TKI treatment 
could potentially also decrease, as was demonstrated for sorafenib 
and pazopanib among other TKIs.6 As regorafenib resembles the 
structure and mechanism of action of sorafenib, an exposure– 
response relationship could be suspected for regorafenib as well. 
In a secondary analysis of the phase III RESORCE trial in pa-
tients with HCC, median overall survival and time- to- progression 
tended to be longer in patients with higher regorafenib exposure 
during the first treatment cycle; however, after correction for sev-
eral covariates, it did not reach statistical significance.12 To our 
knowledge, this trial is the only available evidence on a possible 
exposure – response relationship for regorafenib; therefore, more 
research is necessary on this point.
Acid- suppressive therapy is frequently used by patients with can-
cer, both as prophylaxis for gastrointestinal bleeding due to DDIs 
and as treatment for gastroesophageal reflux disease.13 In 2013, 
Smelick et al.14 reported that up to 33% of all anticancer patients 
used any form of acid- suppressive therapy, most notably a proton 
pump inhibitor (PPI). TKIs often cause stomach complaints or 
gastroesophageal reflux disease, which confronts clinicians with a 
challenge, as the general consensus is to avoid the combination of 
TKIs and acid- suppressive agents. Therefore, registration author-
ities currently recommend investigating this DDI before registra-
tion of a new TKI. However, for regorafenib, this potential DDI 
has not been investigated.
In this study, we assessed the potential pharmacokinetic interac-
tion between esomeprazole and regorafenib. Furthermore, we also 
assessed the potential influence of timing of esomeprazole intake 
relative to that of regorafenib (3 hours before regorafenib ingestion 
or concomitantly).15
RESULTS
Patient characteristics
A total of 31 patients were included, of which 14 patients were 
evaluable for the primary endpoint analysis. The evaluable pa-
tients were equally distributed over the two treatment sequence 
groups. Patients were not evaluable because of various reasons: 
screen failures (n = 4), rapid disease progression during treatment 
(n = 8), and premature treatment interruption (n = 5). Patients 
who developed progressive disease during the study period were 
also equally distributed over the two treatment sequences.
Patient characteristics are detailed in Table 1. All patients 
were diagnosed with mCRC, were of white origin, and were 
predominantly men (71%). Median age was 69 years, and most pa-
tients had an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 1 (86%). All patients used regorafenib 120 mg 
at steady- state on recommendation of the treating physician or due 
to  dosereductions in the first 2 weeks of the trial.
Pharmacokinetics
All obtained pharmacokinetic results are depicted in Table 2. No 
statistical difference in geometric means for regorafenib 0–24- 
hour area under the concentration- time curve (AUC0–24h) was 
found when regorafenib alone was compared with regorafenib and 
esomeprazole concomitantly (relative difference (RD): −3.9%; 
95% confidence interval (CI): −20.5 to 16.1%; P = 1.0) or when 
compared with regorafenib and esomeprazole 3 hours before re-
gorafenib intake (RD: −4.1%; 95% CI: −22.8 to 19.2%; P = 1.0; 
Figure 1). Furthermore, no differences could be identified in peak 
plasma concentration (Cmax) or Tmax for regorafenib. For M- 2 and 
M- 5, no differences could be identified either, although the inter-
individual variability (expressed as coefficient of variation) was 
much higher for all these pharmacokinetic parameters compared 
with regorafenib (Table 2, Figure S1). No sequence or period 
Table 1 Patient characteristics
Characteristic Total
Gender
Male 10 (71%)
Female 4 (29%)
Age, years
Median [IQR] 69 [61–73]
ECOG performance status
0 2 (14%)
1 12 (86%)
Ethnic origin
White 14 (100%)
BMI, kg/m2
Median [IQR] 28.6 [24.1–29.9]
eGFR, mL/minutea
Median [IQR] 82 [77–91]
Liver function (median [IQR])
AST 39 [27–68]
ALT 33 [17–39]
Bilirubin 8 [6–13]
Prior therapy
Surgery 12 (86%)
Radiotherapy 4 (29%)
Chemotherapy 14 (100%)
Monoclonal antibodiesb 9 (64%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body 
mass index; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated 
glomerular filtration rate; IQR, interquartile range.
aeGFR was calculated according to the Chronic Kidney Disease Epidemiology 
Collaboration. bTreatment with monoclonal antibodies included bevacizumab, 
panitumumab, and cetuximab.
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effects were seen for any of the comparisons of the AUC0–24h and 
Cmax (results not shown).
Toxicity
Most common adverse events during the whole study period were 
hoarseness (79%), anorexia (71%), hypertension (71%), hand/
foot skin reaction (64%), fatigue (71%), stomatitis (57%), and 
nausea (50%). In addition, most common blood value disorders 
included transaminase increase (79%), bilirubin increase (50%), 
and hypophosphatemia (29%). The majority of adverse events 
were of low grade; the incidence of toxicity ≥ grade 3 occurred 
mainly as hypertension (64%), anorexia (14%), and hand/foot 
skin reaction (14%). The incidence of adverse events seems com-
parable between different phases. Two patients developed major 
cardiac events, possibly related to regorafenib treatment: myo-
cardial infarction and atrial fibrillation. One patient developed 
Table 2 Regorafenib pharmacokinetics
PK parameters
Regorafenib 
(phase A)
Regorafenib + 
Esomeprazole 
concomitant (phase B)
Regorafenib + 
Esomeprazole 3 hours 
prior (phase C)
Relative 
difference B vs. 
A (95% CI) P value
Relative 
difference C vs. 
A (95% CI) P value
Regorafenib
AUC0–24h  
(μg·hour/mL (CV))
55.9 (40.3) 53.7 (33.5) 53.6 (42.6) −3.9% (−20.5 
to 16.1%)
1.00 −4.1% (−22.8 
to 19.2%)
1.00
Cmax (μg/mL (CV)) 5.3 (28.6) 4.4 (24.2) 4.7 (25.5) −16.5% (−34.9 
to 7.0%)
0.18 −12.1% (−32.0 
to 13.8%)
0.45
Tmax (median 
hours (IQR))
2.5 (2.0–3.0) 2.5 (2.0–3.0) 3.0 (2.5–3.1) 1.00 0.83
M- 2
AUC0–24h 
(μg·hour/mL (CV))
36.6 (71.4) 35.1 (66.2) 35.0 (64.5) −4.0% (−28.6 
to 29.2%)
1.00 −4.3% (−30.1 
to 31.0%)
1.00
Cmax (μg/mL (CV)) 2.9 (72.0) 2.6 (60.9) 2.6 (44.2) −11.0% (−38.7 
to 29.1%)
0.88 −9.3% (−38.1 
to 32.9%)
1.00
Tmax (median 
hours (IQR))
3.3 (2.0–6.0) 2.6 (2.1–3.5) 3.5 (2.5–6.0) 1.00 1.00
M- 5
AUC0–24h 
(μg·hour/mL (CV))
21.9 (103.4) 21.6 (125.7) 20.0 (128.9) −1.4% (−22.5 to 
25.4%)
1.00 −8.9% (−40.4 
to 39.1%)
1.00
Cmax (μg/mL (CV)) 1.6 (118.8) 1.4 (132.4) 1.4 (107.6) −10.4% (−34.6 
to 22.8%)
0.78 −9.1% (−43.2 
to 45.5%)
1.00
Tmax (median 
hours (IQR))
2.6 (1.5–4.0) 2.3 (1.5–8.0) 3.5 (2.5–6.0) 1.00 0.76
AUC0–24h, 0–24- hour area under the concentration- time curve (expressed as geomean μg·hour/mL (CV)); CI, confidence interval; Cmax, peak plasma concentration 
(expressed as geomean μg/mL (CV)); CV, coefficient of variation expressed in %; IQR, interquartile range; PK, pharmacokinetic; Tmax, time until maximum 
concentration (expressed as median hours (IQR)).
Figure 1 Regorafenib area under the curve. Regorafenib exposure compared (a) between phase A (regorafenib alone) and phase B (regorafenib 
concomitantly with esomeprazole), and (b) between phases A and C (regorafenib with esomeprazole 3 hours prior). AUC0–24, 0–24- hour area 
under the concentration- time curve; hr, hour.
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hypertrichosis, although this rare side effect is seen more often 
with other TKIs, such as erlotinib16; to our knowledge, it has not 
been described for regorafenib. All observed adverse events are 
described in Table S1.
DISCUSSION
This randomized, three- phase, crossover clinical trial did not re-
veal a significant pharmacokinetic interaction between esomepra-
zole and regorafenib at the two timepoints studied. Therefore, we 
can conclude that esomeprazole can be combined with regorafenib 
safely, in contrast with other TKIs.
In this study, esomeprazole was used because it exhibits the 
strongest pH- reducing effect of all acid- reducing drugs cur-
rently available.8,17 In addition, esomeprazole does not influ-
ence other enzymes or transporters, such as P- glycoprotein 
(ABCB1), that could potentially influence the pharmaco-
kinetics of regorafenib’s active metabolites M- 2 and M- 5.18 
Therefore, our findings cannot be extrapolated to other 
PPIs, such as pantoprazole, which is known to influence P- 
glycoprotein. We examined two timepoints regarding the in-
take time of esomeprazole (i.e., concomitantly or 3 hours prior 
regorafenib intake), because PPIs are assumed to have their 
maximum acid- reducing effect 3 hours after intake and a pos-
sible interaction would be the strongest at this timepoint.15 
However, even at this timepoint we did not demonstrate an 
influence of esomeprazole on the pharmacokinetics of rego-
rafenib, M- 2, and M- 5.
Regorafenib exhibits low solubility, which is mainly caused by its 
chemical structure as no strong basic or acidic group is attached (re-
gorafenib: 4- [4- ({[4- chloro- 3- (trifluoromethyl)phenyl]carbamoyl} 
amino)- 3- fluorophenoxy]- N-methylpyridine- 2- carboxamide).19 
Furthermore, to improve the solubility, regorafenib is formu-
lated as a solid dispersion consisting of small powder particles 
in which the drug and excipient are integrated.20 Despite this 
formulation, regorafenib exhibits low solubility compared with 
other TKIs. As a result, regorafenib absorption is, in theory, 
less affected by intragastric pH alterations, and the results of 
this study were not totally unexpected. However, because TKI 
absorption is multifactorial, a DDI with PPIs cannot always be 
fully ruled out based on modeling and physiochemical properties 
alone.11 Therefore, a drug interaction should always be verified 
in an in vivo setting, as was done in this study for regorafenib.
In order to reach the required sample size of 14 evaluable 
patients, a total of 31 patients had to be included in the study, 
due to the fact that many patients were not able to complete 
three cycles of regorafenib at 160 or 120 mg due to treatment- 
related adverse events or progression of disease. In addition, 
we aimed to include both patients with mCRC and GIST, but 
mainly patients with mCRC were included, which resulted in 
a possible selection bias. In general, patients with mCRC are 
in a worse condition and more heavily pretreated compared 
with patients with GIST, which could have resulted in more 
adverse events and a higher dropout rate. However, we do not 
think it influenced the pharmacokinetic end points. In addi-
tion, the CORRECT trial demonstrated a median overall sur-
vival increase of 1.4 months compared with placebo in patients 
with mCRC.2 Therefore, it was not completely surprising that 
quite some patients developed early disease progression during 
study treatment, hampering prolonged study participation. In 
addition, all patients eventually used 120 mg at steady- state 
instead of 160 mg, due to known severe treatment- related ad-
verse events (e.g., hypertension), which also occurred in up to 
50% of patients in the registration studies.2–4 Furthermore, be-
cause this study was designed as a pharmacokinetic crossover 
study, we could not compare toxicity between different cycles. 
However, because we found no differences in regorafenib phar-
macokinetics, a difference in exposure- related toxicity seems 
unlikely.
This study was designed to demonstrate a difference based on 
two primary comparisons on regorafenib exposure depending 
on esomeprazole intake time (concomitantly or 3 hours prior). 
Because of the assumption of a difference between those cycles, we 
did not include a bioequivalence analysis. However, the boundaries 
of the adjusted 90% CI of the RDs of the regorafenib AUC found 
in this study almost fit the limits for bioequivalence (B vs. A, RD: 
−3.9%; 90% CI: −18.2 to 12.9%; and C vs. A, RD: −4.1%; 90% 
CI: −20.3 to 15.4%),21 which supports the interpretation of our 
results.
In conclusion, we have shown that esomeprazole did not in-
fluence regorafenib exposure on two different intake timepoints, 
and that these drugs can be combined in clinical practice with-
out the appearance of a significant pharmacokinetic interaction.
METHODS
This study was a randomized, two- armed, three- phase, crossover clinical 
trial in patients using regorafenib. Between May 2016 and February 2018, 
the study was performed at the Erasmus Medical Center, Rotterdam, the 
Netherlands. Approval of the medical ethics committee and the board of 
directors from the Erasmus University Medical Center and the compe-
tent authorities were obtained. The study was registered at the European 
Clinical Trials Database (EudraCT 2015- 005784- 17) and www.clinical-
trials.gov (NCT02800330).
Patients
Patients were included if they were 18 years or older, had a pathological 
confirmed diagnosis of mCRC or GIST, ECOG performance status ≤ 1, 
with adequate kidney and liver function. Patients were excluded if they 
could not abstain from dietary supplements or medication, which could 
interact with regorafenib or esomeprazole, if they could not interrupt 
acid- suppressive therapy, or if they had a known impaired drug absorp-
tion or serious illness that could interfere with study conduct (e.g., infec-
tion, bleeding diathesis or hemorrhage, arterial or venous thrombotic or 
embolic events, uncontrolled hypertension despite optimal medical man-
agement, human immunodeficiency virus, hepatitis, organ transplants, 
or kidney, cardiac, and respiratory diseases). All patients provided writ-
ten informed consent before any study- related procedure was pursued.
Study design
The main objectives of this study were to compare the AUC of re-
gorafenib alone to regorafenib concomitantly used with esomepra-
zole, and to regorafenib used with esomeprazole 3 hours prior, in 
patients with mCRC or GIST. Patients started with regorafenib on 
120 or 160 mg once daily during a loading phase of 14 consecutive days 
(Figure 2). Regorafenib dose adjustments were only allowed during 
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these first 2 weeks of the trial. However, because of (reversible) toxicity, 
the study was allowed to be temporarily interrupted for a maximum of 
one full regorafenib dosing cycle (i.e., 28 days). After reaching steady 
state, patients either used regorafenib alone (phase A) or with esomepra-
zole (40 mg once daily) for 5 consecutive days (phase B and C). During 
phase B of the study, regorafenib was administered concomitantly with 
esomeprazole, whereas during phase C regorafenib was administered 
3 hours after esomeprazole intake, presuming a maximally elevated in-
tragastric pH at the time of regorafenib ingesture.17 Subjects were ran-
domized into two sequence groups (i.e., A- B- C or C- B- A) to rule out 
sequence and time effects (Figure 2).
Pharmacokinetics
Patients were admitted to the hospital on the 21st, the 49th, and the 77th 
day of the trial for pharmacokinetic blood sampling. Blood samples were 
collected before regorafenib administration and at the 0.5, 1, 1.5, 2, 2.5, 
3, 3.5, 4, 6, 8, 12, and 24- hour timepoints after regorafenib administra-
tion (at 10:00 am). Blood samples were collected in 4-mL lithium hep-
arin blood collection tubes, processed into plasma within 10 minutes by 
centrifugation for 10 minutes at 2,500 g (at 4°C), and stored at T<−70°C 
until analysis. Regorafenib, M- 2, and M- 5 plasma concentrations were 
measured using a validated ultraperformance liquid chromatography–
tandem mass spectrometry method (detailed description in Methods 
S1). Pharmacokinetic parameters were calculated by using Phoenix 
WinNonlin version 7.0 (Certara, Princeton, NJ), and included exposure 
expressed as dose corrected AUC0–24h, maximum observed concentration 
(Cmax), and time until maximum observed concentration (Tmax).
Statistical analysis
A difference in systemic exposure to regorafenib of 30% was determined 
to be clinically relevant. Because two primary comparisons were to be 
made (i.e., regorafenib with esomeprazole concomitant or 3 hours prior 
compared with regorafenib alone), a Bonferroni correction was applied. 
The Bonferroni correction was implemented by multiplying the ob-
tained P values by 2 and calculation of 97.5% CIs, which correspond to 
the alpha of 0.025 with the interpretation of Bonferroni corrected 95% 
CIs. It was assumed that the within- patient SD in regorafenib pharma-
cokinetics was 30%. Given a power of 80%, the sample size calculation 
resulted in a required number of 14 evaluable patients.22 Patients were 
considered evaluable when they completed all three phases, including all 
required blood samples.
Analyses of the AUC0–24h and Cmax were performed on log- transformed 
observations because they were assumed to follow a log- normal distribu-
tion.21 Estimates for the mean differences in (log) AUCs and Cmax of rego-
rafenib, M- 2, and M- 5 were obtained for the two comparisons separately 
using a linear mixed effect model with treatment, sequence, and phase as 
fixed effects and subject within sequence as a random effect.23 Variance 
components were estimated based on restricted maximum likelihood 
methods, and the Kenward- Roger method of computing the denomina-
tor degrees of freedom was used. The mean differences and CIs for the 
differences were exponentiated to provide point estimates of the ratio of 
geometric means and CIs for these ratios, which can be interpreted as RDs 
in percentages. The Tmax was analyzed by means of the Wilcoxon signed 
rank test and described with medians and interquartile ranges.
Toxicity was described as the incidence of toxicity per phase and was 
corrected for baseline toxicity by describing only new or worsened toxicity 
compared with baseline. This study was not powered to detect a difference 
in toxicity between treatment phases; therefore, these results only have a 
descriptive character.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure 2 Study procedures. QD, every day. [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure S1. M- 2 and M- 5 AUC.
Table S1. Toxicity.
Methods S1. Detailed description assay regorafenib, M- 2, and M- 5.
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